Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

just to provide some reference for speed of TNBC a

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154867
(Total Views: 463)
Posted On: 01/19/2020 11:07:31 AM
Posted By: OTCnewbie
just to provide some reference for speed of TNBC approval

Keytruda, an approved Merck drug, received BTD approval 4/19/19 for advanced renal cell carcinoma, but still hasn't been received FDA approval for this indication. I'm not saying that Leronlimab won't be approved in 2020, but I think this example (and there are others) should be used as reference. After receiving BTD approval, an FDA approval within 9 months would appear to be record breaking.

Leronlimab may have that potential, but expecting that to happen just isn't reasonable. Yes, its saving lives and the MOA appears to be the real deal in cancer BUT the FDA doesn't work at that speed, as they have shown us in the past. While there were hiccups getting the TNBC trail started last year, I thought it was laughable how people thought it would be approved in 2019, delays or not. This is a great board with a lot of different perspective (WARNING! unpopular opinions to follow), but a lot of people here are blinded by the potential of this drug and the idea of becoming millionaires off a penny stock. I am hoping for this as well, but don't expected it happen as fast as some here. I am long CYDY, believe in the science 99.99%, but also understand how the real world works. I stay mindful to the idea that leronlimab may "set records" for approval in cancer, but don't expect it, or project that view on a daily/weekly basis. I would love for Leronlimab to be approved this Tuesday, but also want to keep my expectations grounded. While this board is very informative and managed much better than Ihub, there may be a little too much positivity, and I wish the skeptics/devils advocates wouldn't all be bullied off.



(7)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us